The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | Advances in perioperative immunotherapy in lung cancer
Rapid advances are being made with increasing investigation into the use of immunotherapy in the perioperative setting. Numerous Phase II trials are underway, including the large LCMC3 study of immune checkpoint inhibitor monotherapy using adjuvant atezolizumab. Jay Lee, MD, UCLA Health, Los Angeles, CA, discusses how these are giving way to Phase III trials looking at immunotherapies in combination with platinum-based chemotherapies and what considerations need to be made in these investigations. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
Disclosures
Advisory board: AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Novartis
Consultancy: Genentech/Roche
Steering committee: Genentech/Roche, Novartis
Research support: Merck
